FDA warns Chaohu Daxin Foodstuffs that its ready-to-eat cooked crawfish from China is adulterated due to an inadequate seafood HACCP plan and poor sanitation.
What happened
FDA inspected the company's seafood plant in Chaohu, Anhui, China, on July 22-23, 2024, and issued a Form 483 listing observations at the close. FDA found the cooking step's critical limits were not proven to kill pathogens, that pesticide hazards and supplier certificates were not controlled, and that a cracked, stained conveyor belt and dripping condensate exposed ready-to-eat crawfish to contamination. The company's August 27, 2024 response was judged not adequate.
What FDA found
The cooking step's critical limits were not shown to reduce pathogens such as Listeria monocytogenes to a safe level, and the literature the company supplied did not support a 6D process.
21 CFR 123.6(c)(3)Cooking temperature and belt speed were not monitored adequately, and recorded belt speeds did not match the values in the HACCP plan.
21 CFR 123.6(c)(3)The receiving step's critical limit did not address chemical contaminants such as pesticides, and supply certificates were missing for seven crawfish suppliers for one batch.
21 CFR 123.6(c)(3)The white conveyor belt touching ready-to-eat cooked crawfish had cracks, cuts and crevices and stayed stained after cleaning.
21 CFR 123.11(b)Condensate dripped from air conditioning units onto food contact surfaces and onto uncovered baskets of ready-to-eat crawfish in the peeling room and walk-in cooler.
21 CFR 123.11(b)
What FDA wants
The company must reply in writing within 15 working days describing specific corrections, including a copy of its hazard analysis and HACCP plan and five consecutive days of completed monitoring records. If corrections cannot be finished in that time, it must explain the delay and state when the remaining violations will be fixed.
Who should pay attention
- US importers and distributors of Chinese cooked crawfish or seafood
- retailers and food service buyers of ready-to-eat seafood
- brands that buy finished product from this contract manufacturer
This is a summary. Read the original letter on fda.gov.